Table 1.

Patient characteristics at baseline

Interim populationOverall population
n = 34N = 86
Group 1Group 2Group 1Group 2
n = 17n = 17an = 40n = 46a
Age, y
 Median (range)59 (52–75)57 (44–72)59 (39–75)61 (40–74)
WHO performance statusn (%)n (%)n (%)n (%)
 05 (29.4)9 (52.9)18 (45.0)24 (52.2)
 111 (64.7)7 (41.2)19 (47.5)18 (39.1)
 21 (5.9)1 (5.9)3 (7.5)4 (8.7)
Sexn (%)n (%)n (%)n (%)
 Male11 (64.7)11 (64.7)24 (60.0)29 (63.0)
Primary tumor locationn (%)n (%)n (%)n (%)
 Colon10 (58.8)15 (88.2)28 (70.0)34 (73.9)
 Rectum7 (41.2)2 (11.8)12 (30.0)12 (26.1)
Metastatic sitesn (%)n (%)n (%)n (%)
 Liver9 (52.9)15 (88.2)29 (72.5)39 (84.8)
 Lung10 (58.8)2 (11.8)14 (35.0)12 (26.1)
 Peritoneum02 (11.8)5 (12.5)9 (19.6)
  • NOTE: Group 1: UGTA1*1/UGTA1*1; Group 2: UGT1A1*1/UGT1A1*28.

    a1 patient in group 2 was never treated because brain metastases were discovered after the patient's inclusion.